4Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2. 2013: featured updates to the NCCN Guidelines [ J]. J Natl Compr Canc Netw, 2013,11(5) :531-546.
6Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice[J]. J Dig Dis, 2007,8(1):8-14.
7Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies[ J]. J Dig Dis, 2007,8( 1 ) : 15-22.
8Mizuno S, Miki I, lshida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis[ J]. Dig Dis Sci, 2010,55 ( 11 ) : 3132-3137.
9Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsino- gen and gastrin 17 are predictive of extensivegastrie atrophy with high-risk of early gastric cancer[ J]. Tohoku J Exp Med, 2011, 223(1) :35-44.
10Manojlovic N, Babic D, Filipovic-Ljeshovie I, et al. Anti Helico- bacter pylori IgG and IgA response in patients with gastric cancer and chronic gastritis [ J ]. Hepatogastroenterology, 2008,55 ( 82- 83) :807-813.
